New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Leukemia and Lymphoma

Volumn 50, Issue 7, 2009, Pages 1148-1154

  Mascarenhas, Cintia C ^a   Cunha, Anderson F ^a   Miranda, Eliana C ^a   Zulli, Roberto ^a   Silveira, Rosana A ^a   Costa, Fernando F ^a   Pagnano, Kátia B ^a   De Souza, Cármino A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

BCR ABL mutations; CML; D HPLC; Survival; Tyrosine kinase inhibitors

Indexed keywords

ABELSON KINASE; ARGININE; ASPARTIC ACID; BCR ABL PROTEIN; CYSTEINE; DASATINIB; GENOMIC DNA; GLUTAMIC ACID; GLYCINE; IMATINIB; ISOLEUCINE; LEUCINE; METHIONINE; NILOTINIB; PHENYLALANINE; PROTEIN TYROSINE KINASE INHIBITOR; SERINE; THREONINE; VALINE;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA EXTRACTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENZYME ACTIVITY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; OVERALL SURVIVAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 68449086340     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902930496     Document Type: Article

References (28)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-1340.
2. Kujawski L, Talpaz M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma 2007;48:2310-2322.
3. Khorashad JS, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658-663.
4. Branford S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-283.
5. Soverini S, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-4109.
6. Pfeifer H, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007;110:727-734.
7. Kimura S. Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone. Recent Patents Anticancer Drug Discov 2006;1:347-355.
8. Soverini S, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004;50:1205-1213.
9. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: Keeping resistance in check. Expert Opin Investig Drugs 2008;17:865-878.
10. Nicolini FE, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006;20:1061-1066.
11. Ernst T, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186-192.
12. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-2249.
13. Deininger MW, et al. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 2004;18:864-871.
14. Shah NP, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
15. Gorre ME, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
16. Roche-Lestienne C, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-1018.
17. Baccarani M, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809-1820.
18. Hochhaus A, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-2196.
19. Soverini S, et al. Resistance to dasatinib in Philadelphiapositive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:401-404.
20. Shah NP, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562-2569.
21. Irving JAE, et al. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib. Clin Chem 2004;50:1233-1237.
22. Chomel JC, et al. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML). Leuk Res 2009;33:551-555.
23. Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008;1:15.
24. Ernst T, et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2008;93:1389-1393.
25. Wolford JK, et al. High-throughput SNP detection by using DNA pooling and denaturing high performance liquid chromatography (DHPLC). Hum Genet 2000;107:483-487.
26. Baumer A, et al. A novel MSP/DHPLC method for the investigation of the methylation status of imprinted genes enables the molecular detection of low cell mosaicisms. Hum Mutat 2001;17:423-430.
27. Emmerson P, et al. Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes. Hum Mutat 2003;21: 112-115.
28. Chien JH, et al. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leuk Res 2008;32: 1724-1734.